Pharmacy Program (Laba), Clinical and Health Sciences Unit, The University of South Australia, Adelaide, Australia; The Centre for Health Economics Research and Evaluation (Laba), University of Technology Sydney, Ultimo, Australia; Centre for Health Services and Policy Research (Worthington, Chen, Bansback, Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; Department of Epidemiology, Biostatistics, and Occupational Health (Chan), McGill University, Montréal, Que.
CMAJ Open. 2022 Dec 13;10(4):E1059-E1066. doi: 10.9778/cmajo.20210185. Print 2022 Oct-Dec.
Choosing Wisely is a high-profile campaign seeking to reduce the use of low-value care. We investigated the impact of a Choosing Wisely Canada recommendation against using a combination of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the management of hypertension, heart failure or diabetic nephropathy on population-level use of these medications in British Columbia, Canada.
We identified all people (any age) who were continuously registered with BC's Medical Service Plan between 2010 and 2017 with the targeted conditions. Using prescription claims data and an interrupted time-series analysis, we estimated the number of people on combination therapy per month, the proportion of days covered (PDC) by combination therapy per month and proportion of all combination prescriptions started per month in the 2 years before and after the introduction of the recommendation on Oct. 29, 2014.
Of 1 104 593 people (mean age 65 yr, standard deviation 16 yr) in our study cohort, 4.6% were exposed to combination therapy, largely prescribed by family physicians (84%). The number of people on combination therapy and the PDC were declining before the recommendation, but the proportion of combination prescriptions started in the 2 years before the recommendation was increasing. After the recommendation, we observed no statistically significant changes in any outcome. The pre-existing downward trend of the monthly number of people decelerated (16.8, 95% confidence interval [CI] 14.0 to 19.5) and the proportion of prescriptions started increased (0.13%, 95% CI 0.08% to 0.18%).
The Choosing Wisely Canada recommendation against using a combination of ACE inhibitors and ARBs was not associated with reduced combination therapy use in the targeted conditions. The observed pre-existing declines in this practice questions the process of selecting recommendations, and the optimal implementation and value of Choosing Wisely campaigns without other reinforcing interventions.
“明智选择”是一项旨在减少低价值医疗服务的高知名度活动。我们调查了加拿大“明智选择”推荐意见,即反对将血管紧张素转换酶(ACE)抑制剂和血管紧张素受体阻滞剂(ARB)联合用于治疗高血压、心力衰竭或糖尿病肾病,对不列颠哥伦比亚省(加拿大)人群中这些药物使用的影响。
我们确定了 2010 年至 2017 年间连续登记在不列颠哥伦比亚省医疗服务计划中的所有(任何年龄)患有目标疾病的人。使用处方数据和中断时间序列分析,我们估计了 2014 年 10 月 29 日推荐意见发布前后 2 年内每月联合治疗人数、每月联合治疗天数覆盖率(PDC)和每月所有联合处方开始比例。
在我们的研究队列中,有 1104593 人(平均年龄 65 岁,标准差 16 岁),其中 4.6%接受了联合治疗,主要由家庭医生开具处方(84%)。在推荐意见之前,接受联合治疗的人数和 PDC 呈下降趋势,但推荐意见之前 2 年内开始联合治疗的比例呈上升趋势。推荐意见后,我们没有观察到任何结果的统计学显著变化。每月接受联合治疗人数的先前下降趋势减缓(16.8,95%置信区间 [CI] 14.0 至 19.5),开始处方的比例增加(0.13%,95% CI 0.08%至 0.18%)。
加拿大“明智选择”反对将 ACE 抑制剂和 ARB 联合用于治疗目标疾病的建议,并未导致联合治疗的使用减少。在没有其他强化干预措施的情况下,观察到这种做法的先前下降趋势,对建议的选择过程以及明智选择活动的最佳实施和价值提出了质疑。